(QTTB) Q32 Bio - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 214m USD | Total Return: 696.9% in 12m
Avg Turnover: 6.93M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 15.6% YoY
Altman Z'' -1.24 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w
Q32 Bio Inc. (NASDAQ: QTTB) is a clinical-stage biotechnology firm focused on developing biologics to treat autoimmune and inflammatory diseases. Its primary pipeline candidate, Bempikibart (ADX-914), is a monoclonal antibody targeting the interleukin-7 receptor alpha to regulate adaptive immune responses. The company is also advancing ADX-096, a fusion protein designed for tissue-targeted complement inhibition in ophthalmologic indications.
The biotechnology sector typically requires significant capital for research and development, as clinical-stage companies often operate without recurring revenue until regulatory approval is secured. Q32 Bio utilizes a specialized business model centered on targeted protein engineering to address immune system dysfunctions.
Investors may find additional financial metrics and valuation models for this ticker on ValueRay.
- Bempikibart Phase 2 clinical trial readouts for atopic dermatitis and alopecia
- ADX-096 advancement into Phase 2 trials for complement-mediated diseases
- Cash runway and capital allocation to fund operations through 2026
- Competitive landscape for IL-7R and TSLP targeted autoimmune therapies
| Net Income: 33.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA 40.08 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.43 > 3% & CFO -27.4m > Net Income 33.2m |
| Net Debt (-34.3m) to EBITDA (22.2m): -1.55 < 3 |
| Current Ratio: 5.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.1m) vs 12m ago 15.56% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 75.29% > 50% (prev 0.0%; Δ 75.29% > 0%) |
| Interest Coverage Ratio: 21.79 > 6 (EBIT TTM 21.8m / Interest Expense TTM 1.00m) |
| A: 0.73 (Total Current Assets 57.2m - Total Current Liabilities 10.7m) / Total Assets 63.7m |
| B: -3.34 (Retained Earnings -212.6m / Total Assets 63.7m) |
| C: 0.31 (EBIT TTM 21.8m / Avg Total Assets 71.4m) |
| D: 2.67 (Book Value of Equity 46.3m / Total Liabilities 17.4m) |
| Altman-Z'' = -1.24 = CCC |
As of June 18, 2026, the stock is trading at USD 12.91 with a total of 251,165 shares traded.
Over the past week, the price has changed by +0.31%,
over one month by +124.52%,
over three months by +110.60% and
over the past year by +696.91%.
Q32 Bio has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold QTTB.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.3 | 10.4% |
P/E Trailing = 4.5468
P/S = 3.9885
P/B = 4.6169
Revenue TTM = 53.7m USD
EBIT TTM = 21.8m USD
EBITDA TTM = 22.2m USD
Long Term Debt = 1.94m USD (from longTermDebt, last quarter)
Short Term Debt = 6.24m USD (from shortTermDebt, last quarter)
Debt = 16.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.47m
Net Debt = -34.3m USD (calculated: Debt 16.5m - CCE 50.8m)
Enterprise Value = 180.0m USD (214.3m + Debt 16.5m - CCE 50.8m)
Interest Coverage Ratio = 21.79 (Ebit TTM 21.8m / Interest Expense TTM 1.00m)
EV/FCF = -6.57x (Enterprise Value 180.0m / FCF TTM -27.4m)
FCF Yield = -15.22% (FCF TTM -27.4m / Enterprise Value 180.0m)
FCF Margin = -51.00% (FCF TTM -27.4m / Revenue TTM 53.7m)
Net Margin = 61.86% (Net Income TTM 33.2m / Revenue TTM 53.7m)
Gross Margin = unknown ((Revenue TTM 53.7m - Cost of Revenue TTM 391k) / Revenue TTM)
Tobins Q-Ratio = 2.83 (Enterprise Value 180.0m / Total Assets 63.7m)
Interest Expense / Debt = 6.07% (Interest Expense 1.00m / Debt 16.5m)
Taxrate = 0.0% (0.0 / 29.8m)
NOPAT = 21.8m (EBIT 21.8m * (1 - 0.00%))
Current Ratio = 5.36 (Total Current Assets 57.2m / Total Current Liabilities 10.7m)
Debt / Equity = 0.36 (Debt 16.5m / totalStockholderEquity, last quarter 46.3m)
Debt / EBITDA = -1.55 (Net Debt -34.3m / EBITDA 22.2m)
Debt / FCF = 1.25 (negative FCF - burning cash) (Net Debt -34.3m / FCF TTM -27.4m)
Total Stockholder Equity = 14.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 46.58% (Net Income 33.2m / Total Assets 63.7m)
RoE = 230.7% (Net Income TTM 33.2m / Total Stockholder Equity 14.4m)
RoCE = 133.3% (EBIT 21.8m / Capital Employed (Equity 14.4m + L.T.Debt 1.94m))
RoIC = 38.52% (NOPAT 21.8m / Invested Capital 56.6m)
WACC = 8.11% (E(214.3m)/V(230.8m) * Re(8.27%) + D(16.5m)/V(230.8m) * Rd(6.07%) * (1-Tc(0.0)))
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.61 | Cagr: 92.66%
[DCF] Fair Price = unknown (Cash Flow -27.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.56 | Chg30d=-46.84% | Revisions=N/A | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.41 | Chg30d=-4.10% | Revisions=N/A | Analysts=5
EPS current Year (2026-12-31): EPS=-1.82 | Chg30d=+13.11% | Revisions=+20% | GrowthEPS=-175.0% | GrowthRev=-98.1%
EPS next Year (2027-12-31): EPS=-2.23 | Chg30d=+34.15% | Revisions=+33% | GrowthEPS=-22.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +33%